Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.61 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27400280 | 0.85 | HPGD (0.72) | HPGDHSD11B1CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL3320998 | 0.84 | HPGD (0.75) | HPGDHSD11B1CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL14002183 | 0.83 | HPGD (0.65) | HPGDHSD11B1CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL3455848 | 0.83 | HPGD (1.00) | HPGDHSD11B1CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL3319980 | 0.80 | HPGD (0.64) | HPGDHSD11B1CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL1548543 | 0.79 | HPGD (0.67) | HPGDHSD11B1CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL14705916 | 0.78 | ALDH1A1 (0.57) | HSD11B1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL11736108 | 0.77 | ALDH1A1 (0.65) | HPGDHSD11B1CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL11739611 | 0.77 | HPGD (0.77) | HPGDHSD11B1CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL4105154 | 0.76 | EPHX2 (0.71) | HPGDHSD11B1ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017974-B2 | Adamantanecarboxylic acid benzyl amide derivative compound and skin whitening composition comprising same | AMOREPACIFIC CORPORATION (KR) | 2024-06-25 | — | — | US | disclosed |
| WO-2005012304-A2 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017974-B2 | Adamantanecarboxylic acid benzyl amide derivative compound and skin whitening composition comprising same | TYR, DDC, AANAT | HPGD 555/4885HSD11B1 1164/4885CYP17A1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.